UnitedHealth Just Beat EPS Estimates by 30% and Hit a 2-Year Low on Medical Costs. Is the Worst Over?

Key Stats for UNH Stock

• 52-Week Range: $234.60 – $461.62
• Current Price: $420.57
• Street Target Price: ~$475
• NTM P/E: ~20x
• YTD Return: +25%
• Dividend Yield: 2.1%
• Market Cap: ~$382B

Value your favorite stocks like UnitedHealth with TIKR’s Guided Valuation Model (It’s free) >>>

From Crisis to Recovery: What UNH’s Q2 Numbers Actually Show

UnitedHealth Group (UNH) operates two distinct businesses under one roof. UnitedHealthcare is the insurance arm, covering over 50 million people across employer-sponsored plans, Medicare Advantage, Medicaid, and individual markets.

Optum is a health services business, running pharmacy benefit management through Optum Rx, physician practices through Optum Health, and data analytics through Optum Insight. Together, they make UNH the largest health company in the United States by revenue.

The past twelve months tested both businesses severely. Medicare Advantage, the government-funded private insurance program for Americans 65 and older, saw a surge in medical utilization as patients sought care that had been deferred during the pandemic, while GLP-1 specialty drug costs added further pressure.

The medical care ratio, the percentage of premium revenue paid out in medical claims and the single most important profitability metric for a health insurer, deteriorated sharply. Historically, UNH operated in the 82-84% range. By Q4 2025, the ratio had blown out badly enough that the company suspended full-year earnings guidance entirely.

Q2 2026 delivered a meaningful reversal. Adjusted EPS came in at $6.38, beating the $4.91 consensus by 30%. The medical care ratio improved to 86.7%, down from 89.4% in Q2 2025 and well below the 88.5% expected by analysts, marking its lowest level in eight quarters. Optum’s operating income climbed 29% to nearly $4 billion. Operating cash flow reached $11.1 billion.

Management reinstated and raised full-year adjusted EPS guidance to $19.50-$20.00. The Beats and Misses table below shows the full arc across five quarters, the catastrophic Q4 2025 miss, and the sharp reversal since.

The challenges have not disappeared entirely. Medicare Advantage membership contracted by roughly 965,000 since year-end 2025 as UNH exited unprofitable markets. Medicaid margins remain pressured as reimbursement rates lag medical cost trends.

An active DOJ civil and criminal investigation into Medicare Advantage billing practices represents a legal overhang with an uncertain timeline and outcome.

See analysts’ growth forecasts and price targets for UNH (It’s free) >>>

Is UNH Cheap, Expensive, or Somewhere in Between?

Understanding where UNH trades relative to its own history matters more than usual right now, because the stock’s absolute earnings are temporarily distorted by the cost crisis.

NTM EV/EBITDA cuts through some of that noise by focusing on forward earnings power rather than damaged trailing numbers.

The long-term mean on that metric sits at 12.24x. During UNH’s peak years of 2021-2022, the multiple ran as high as 17.95x as investors paid a premium for what looked like an uninterruptible compounder. At the crisis lows of late 2025 and early 2026, it compressed toward 8-9x as confidence collapsed.

The current reading of 13.48x sits modestly above the long-term average, implying investors believe the recovery is real without yet fully pricing in a return to peak profitability.

The stock is not cheap at current levels, and recovering toward the historical mean after a crisis does not make a business a bargain.

It makes it fairly priced if the recovery holds. The DOJ investigation is the variable that makes the multiple math genuinely difficult to underwrite with confidence.

Access Professional Tools to Analyze UNH stock on TIKR for Free →

What the Valuation Model Says About UNH Stock

The TIKR valuation model mid-case target comes out to around $723, representing a potential total return of roughly 72% at around 13% annualized over 4.4 years.

The model assumes revenue growing at around 5.7% annually, net income margins recovering to roughly 5.2%, and EPS compounding at around 12% per year. Multiple compression of about 0.7% per year is baked in, meaning the returns are driven by earnings normalization rather than re-rating.

The Street consensus target of around $475 implies roughly 13% upside from current levels.

The high case reaches around $1,324 at roughly 14.6% annualized, assuming the DOJ investigation resolves favorably, and medical costs normalize fully. The low case still reaches around $864 at roughly 8.9% annualized, reflecting a slower but not derailed recovery.

Should You Buy UNH Stock?

UNH’s Q2 results were substantially better than the market feared, and the reinstated guidance signals that management believes the medical cost improvement is durable. The TIKR mid-case offers a credible path to double-digit annualized returns if earnings normalization continues.

The DOJ investigation is the risk that cannot be sized precisely, civil and criminal probes into Medicare Advantage practices at this scale have no clear precedent, and the outcome could range from a manageable settlement to something more disruptive.

Investors comfortable with that uncertainty and willing to underwrite the earnings recovery will find the setup more interesting than UNH’s recent history might suggest.

Model UnitedHealth’s fair value scenarios in under 60 seconds (Free with TIKR) >>>

Looking for New Opportunities?

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!